Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Gowey Research Group Pllc currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is reviewed by 1 distinct examiner, SPAINE, ROBERT FRANKLIN, in 1 distinct art unit. As the busiest examiner, SPAINE, ROBERT FRANKLIN handles the 1 pending action that makes up the company's current workload. This represents a highly focused prosecution effort within a single technical domain, which can lead to a more predictable interaction with the office.
The concentration of the 1 pending office action within 1 distinct art unit allows the applicant to focus their technical arguments on the specific standards of that group. Because SPAINE, ROBERT FRANKLIN is the only official involved, practitioners should prioritize understanding this 1 distinct examiner's past decisions and preferred claim structures. This streamlined prosecution path reduces the need for coordinating across different technical groups but also means the company's current biotech portfolio depends entirely on the resolution of this single matter. Success will require a strategy that directly addresses the 1 distinct art unit's standards.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18164368 | METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING | SPAINE, ROBERT FRANKLIN | 87d overdue |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18164368 | METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING | SPAINE, ROBERT FRANKLIN | 1655 | §103§112 | Non-Final OA | 87d overdue | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGowey Research Group Pllc has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert Franklin Spaine has the most, with 1 of Gowey Research Group Pllc's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
